doi:10.5603/GP.a2020.0173
Additionally, research suggests that semaglutide may also reduce A1C levels in people with or without diabetes, making it a dual-purpose treatment [5]
162,163 The pharmacological basis of their action is increasingly being elucidated through both in vitro and in vivo experimental models, especially in conditions like IBS, peptic ulcers, GERD, and IBD, such as Crohns disease and ulcerative colitis
Although these changes are generally not clinically significant in healthy individuals, they could pose a greater risk in populations predisposed to metabolic disorders, such as prediabetes or type 2 diabetes
[DOI] [PubMed] [Google Scholar] 107.Smeland OB, Meisingset TW, Borges K, Sonnewald U
Unlike dopaminergic or GABAergic compounds that cause receptor downregulation, c-Met receptor density doesn't decrease with prolonged agonist exposure in published models